Key Insights:
- Q4 revenue grew 5% year-over-year to $619 million.
- Fourth quarter consumable revenue represented 66% of total revenue or $407 million, an increase of 18% compared to the fourth quarter of 2015.
- Sequencing consumable revenue grew 20% year-over-year to $331 million.
- Services and other revenue equaled $94 million, with strength in genotyping services and sequencing instrument maintenance contracts offset by an expected decline in NIPT service revenue.
- Adjusted gross margin for the fourth quarter was 69.9%, lower sequentially by 260 basis points.
- Adjusted research and development expenses in Q4 were $121 million, or 19.5% of revenue.
- Adjusted SG&A expenses for the quarter equaled $130 million, or 20.9% of revenue.
- Adjusted operating margins were 29.5% compared to 34.4% in the third quarter.

Financial Metrics:
- Q4 GAAP net income was $124 million and EPS was $0.84 per diluted share.
- Q4 non-GAAP net income was $126 million or $0.85 of EPS.
- Cash flow from operations equaled $280 million.
- Q4 free cash flow was $199 million.
- The company ended the quarter with approximately $1.6 billion in cash and short-term investments.
- Full year, non-GAAP EPS guidance is expected to be $3.60 to $3.70.

Future Outlook:
- The company is projecting Q1 revenue of $580 million to $595 million.
- Total company revenue is expected to grow 10% to 12% in 2017, including revenue contribution from GRAIL and Helix, as well as a currency headwind.
- Q1 GAAP earnings per diluted share is expected to be $0.51 to $0.56 and non-GAAP earnings per diluted share of $0.60 to $0.65.
- Full year, GAAP earnings per diluted share is expected to be $3.25 to $3.35 and non-GAAP EPS is expected to be $3.60 to $3.70.
- The company expects 2017 stock-based compensation to be 6% of revenue on average.

Based on these insights and financial metrics, the company's strong revenue growth and positive cash flow position indicate a solid financial performance. The expected growth in 2017, despite headwinds from currency and investments in GRAIL and Helix, demonstrates the company's resilience and potential for future growth. Therefore, an 'overweight' investment stance is recommended for this company.